Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 23 Jan 2019
Discrete choice experiments in health economics: past, present and future
23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health. ...
Posted by Michael Wonder on 20 Oct 2018
Cost, context, and decisions in health economics and health technology assessment
18 October 2018 - This study is an attempt to demystify and clarify the idea of cost in health economics ...
Posted by Michael Wonder on 27 Sep 2018
With payers under pressure, biosimilars must demonstrate their value
27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...
Posted by Michael Wonder on 10 Aug 2018
Biosimilars for insulin: a cost-saving alternative?
11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...
Posted by Michael Wonder on 23 Apr 2018
Cost-effectiveness thresholds: the past, the present and the future
23 April 2018 - Cost-effectiveness (CE) thresholds are being discussed more frequently and there have been many new developments in this ...
Posted by Michael Wonder on 13 Apr 2018
Decision components of NICE's technology appraisals assessment framework
10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...
Posted by Michael Wonder on 22 Mar 2018
Resolving the “cost-effective but unaffordable” paradox: estimating the health opportunity costs of non-marginal budget impacts
22 March 2018 - Considering whether or not a proposed investment (an intervention, technology, or program of care) is affordable is ...
Posted by Michael Wonder on 20 Feb 2018
Beyond QALYs: multi-criteria based estimation of maximum willingness to pay for health technologies
20 February 2018 - The QALY is a useful outcome measure in cost-effectiveness analysis. But in determining the overall value of ...
Posted by Michael Wonder on 28 Jan 2018
Is “end of life” a special case? Connecting Q with survey methods to measure societal support for views on the value of life-extending treatments
19 January 2018 - Preference elicitation studies reporting societal views on the relative value of end-of-life treatments have produced equivocal results. ...
Posted by Michael Wonder on 24 Jan 2018
How excluding some benefits from value assessment of new drugs impacts innovation
23 January 2018 - Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently ...
Posted by Michael Wonder on 23 Jan 2018
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries
23 January 2018 - Although health technology assessment systems base their decision making process either on economic evaluations or comparative clinical ...
Posted by Michael Wonder on 11 Dec 2017
NHS advises GPs not to prescribe “low value” drugs
30 November 2017 - NHS England will issue guidance to GPs and commissioners to limit the prescribing of “low value” ...
Posted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...